ABSTRACT Cactaceae species are karyotypically well-known with x = 11 and chromosome number variation due mainly to polyploidization. However, both assumptions are based on descriptive observations without taking an evolutionary framework of Cactaceae into account. Aiming to confirm these hypotheses in an evolutionary context, we obtained chromosome numbers for 20 species of Cactoideae, performed an extensive review of chromosome number for the family, and analyzed these data using a phylogenetic approach. The karyotypes presented here were characterized by CMA/DAPI banding, and for six species 5S and 45S rDNA sites were located. Our data, along with a survey of the literature, reinforce the long-standing hypothesis of a x = 11 as the base chromosome number for Cactaceae. They also reinforce the relevance of polyploidy in karyotype evolution of cacti, although polyploidy was important just after the diversification of subfamilies Maihuenioideae and Pereskioideae. Despite the homogeneous chromosome complements observed among cacti, chromosome banding and FISH techniques revealed informative characteristics, allowing the identification of chromosome synapomorphies, such as proximal CMA+ bands in Melocactus and proximal 5S rDNA in Pilosocereus, indicating the taxonomic potential of chromosome characterization in cacti.

INTRODUÇÃO: O stent farmacológico eluidor de paclitaxel, não-polimérico, Amazonia® PAX não mostrou diferença na reestenose coronária ou eventos clínicos aos 4 meses de evolução quando comparado com o stent Taxus®. Entretanto, o desempenho do stent Amazonia® PAX em cenários de maior complexidade e com seguimento angiográfico mais longo ainda não foi demonstrado. MÉTODOS: O Estudo PAX-B foi um estudo prospectivo, não-randomizado, multicêntrico, que avaliou os resultados tardios de pacientes tratados com o stent Amazonia® PAX. O desfecho primário foi a perda tardia do lúmen intrastent. RESULTADOS: Foram incluídos 103 pacientescom média de idade de 61,3 ± 11,4 anos, 26,2% eram diabéticos, 24,3% apresentaram-se com síndrome coronária aguda e 71,6% tinham lesões tipo B2/C. Implante de múltiplos stents ocorreu em 4,7% dos casos e o sucesso angiográfico foi de 100%. Na fase hospitalar, a taxa de infarto agudo do miocárdio periprocedimento foi de 3,9%, e um desses eventos levou à revascularização da lesão-alvo (RLA). No seguimento angiográfico de 9 meses, a mediana da perda tardia do lúmen intrastent foi de 0,91 [0,50; 1,21] mm. As taxas cumulativas de eventos cardíacos adversos maiores nos seguimentos de 6 meses, 9 meses e 12 meses foram, respectivamente, de 7,8%, 18,5% e 21,3%, principalmente em decorrência de RLA. Não se observou morte ou trombose de stent em 12 meses. CONCLUSÕES: O stent Amazonia® PAX demonstrou excelentes resultados imediatos e alto perfil de segurança. Entretanto, as taxas de recorrência angiográfica foram relativamente altas, em razão da pouca eficácia na inibição da formação de hiperplasia neointimal.

BACKGROUND: The non-polymeric paclitaxel-eluting sent Amazonia® PAX did not show differences in the occurrence of coronary restenosis or clinical events after 4 months of follow-up when compared with the Taxus® stent. However, the performance of the Amazonia® PAX stent in more complex cases and with longer angiographic follow-up has not been demonstrated. METHODS: The PAX-B study was a prospective, non-randomized, multicenter study assessing the late follow-up of patients treated with the Amazonia® PAX stent. The primary outcome was in-stent late lumen loss. RESULTS: One hundred and three patients with mean age of 61.3 ± 11.4 years were included, 26.2% were diabetics, 24.3% had acute coronary syndromes and 71.6% had type B2/C lesions. Multiple stents were performed in 4.7% of the cases and angiographic success was 100%. During hospitalization, the periprocedural acute myocardial infarction rate was 3.9% and one of these events led to target lesion revascularization (TLR). At 9-month angiographic follow-up, the median in-stent late lumen loss was 0.91 [0.50; 1.21] mm. The cumulative rates of major adverse cardiac events at the 6-month, 9-month and 12-month follow-up were 7.8%, 18.5% and 21.3%, respectively, mostly due to TLR. There was no death or stent thrombosis at 12 months. CONCLUSIONS: The stent Amazonia® PAX demonstrated excellent immediate results and high safety profile. However, angiographic recurrence rates were relatively high, due to low efficacy in inhibition of neointimal hyperplasia.

Information about the distribution and insertion numbers of many transposable elements is restricted to few species of Drosophila, although these elements are widely distributed throughout the genus. The aim of this work was to describe the distribution and insertion numbers of four retrotransposons (copia, gypsy, micropia, I) and four transposons (hobo, mariner, Minos and Bari-1) in the saltans group of Drosophila. Our data shows that, except for mariner, all the other elements are widespread within the saltans group and show variable insertion numbers of up to 24 copies.